Excellent cells
and media

High performance

Produced in the US or EU

Our media are produced under GMP conditions as well as EMA and FDA regulations. The media are available in liquid or in powder formulation.

Highest regulatory compliance

Our culture media are completely synthetic.
They are free of

• Serum
• Animal components
• Hydrolysate
• Growth factor

Our media at a glance

ORCHID

Culture medium for HEK293 suspension cells.

Medium for production of virus and recombiant proteins. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

IVY

Culture medium for HEK293 suspension cells.

Medium for viral vector replication and transient expression. Serum-free, animal component-free, hyrdolysate-free and fully defined.

Learn more

MIMOSA

Culture medium for MRC-5 suspension cells.

Medium for virus production. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

LILY

Single cell cloning medium for transfected CHO DG44 cells.

Medium for clonal growth of single cells. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

DAISY

Single cell cloning medium for HEK293 Cells

Medium for clonal growth of single cells. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

CAMELLIA

Culture medium for MDCK cells.

Medium for production of virus and recombiant proteins. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

IMORTELLE

Culture medium for VERO suspension cells.

Medium for production of virus and recombiant proteins. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

LOTUS

Culture medium for adherent VERO cells.

Medium for production of virus and recombiant proteins. Serum-free, animal component-free, hydrolysate-free and fully defined.

Learn more

ROSE

Culture medium for BHK-21 suspension cells.

Medium for virus production. Serum-free, animal component-free, hydrolysate-free and fully defined. (Licensed-out)

IXORA

Culture medium for CHO K1 cells.

Medium for recombinant protein production. Serum-free, animal component-free, hydrolysate-free, fully defined.

Learn more

IRIS

Culture medium for CHO DG44 cells.

Medium for recombinant protein production. Serum-free, animal component-free, hydrolysate-free, fully defined.

Learn more

COSMOS

Culture medium for CHO S cells.

Medium for recombinant protein production. Serum-free, animal component-free, hydrolysate-free, fully defined.

Learn more

Platforms, more than their single modules

Quick - Predictable - Reproducible

Punctual solutions seldom bring sustainable value to clients, Therefore we have an integral approach. We have developed platform technologies for the manufacturing of recombiant proteins and vaccines. Our platforms consist of host cell lines, culture media and cell cultivation methodology from cell thaw up to harvest of a production bioeactor.

Sustainable

Using platforms we avoid repetitive development of culture media or bioreactor processes. Our platforms offer a holistic approach to our clients with the goal of reaching he market quickly. Our platforms consider all aspects of manufacturing while developing the process such as IP, regulation, scalability and robustness.

Our platforms at a glance

ProteinMax  Platform for protein production. VaccineMax  Platform for vaccine production. GlycoShift  Platform for glycoengineering. NutriBalance  Platform for media development.

ProteinMax-

platform for protein production

Protein production with CHO cells

We have a large platform for rapid production of target proteins on a large scale with the desired quality. The protein platform is a combination of multiple other platforms.

The protein platform consists of the following subplatforms:

1. Cell line generation platform consisting of vector, host line and the clone selection process.
2. Culture media platform consisting of the single cell cloning medium, the basal medium and the feed media.
3. Our GlycoShift platform consisting of nutrient cocktails for altering the glycosylation.
4. The bioreactor platform made up of scaled down models of larger bioreactors for fed-batch processes including cell harvesting.

Cell line generation

The platform consists of our proprietary expression vector, the CHO DG44 host cell line and a clone selection process.

We offer cell line generation to our clients as a service. Multiple cell lines are generated as long as all of them are expressing biosimilarities. Our focus in cell line generation is the biosimilarity. Therefore we use our platform known as GlycoShift during the cell line generation.

VaccineMax-

platform for vaccine production

We have multiple platforms for producing any vaccine rapidly with high reproducibility and scalability.

Our platforms have been proven in the production of vaccines against Covid -19, foot and mouth diseases, rabies, AAV as well as LV and AV.

Virus and recombinant protein production with HEK293 cells.

Currently in use for 2 different vaccine projects against SARS-CoV-2.

The platform contains suspension adapted HEK293 cells. Animal component free and cultivated in a high titer fed-batch process and cell harvest procedure.

Learn more

Viral vector production and transient protein expression with HEK293 cells.

This platform is used in vaccine development against Covid-19.

The platform contains suspension adapted HEK293 cells. Animal component free, transfection medium and transient expression protocol.

Learn more

Virus production with adherent VERO cells.

Currently in use for 2 different vaccine projects against SARS-CoV-2.

The platform contains adherent growing VERO cells. They are animal component free utilising a microcarrier based bioreactor process.

Learn more

Virus production with suspension adapted BHK-21 cells.

Used in viral production of Foot/Mouth disease and rabies across 3 continents.

The platform contains suspension adapted BHK-21 cells. They are animal component free and stirred in our bioreactor tank process.

Learn more

GlycoShift-


platform for glycoengineering

GlycoShift



We have identified cellular nutrients that shift the secondary metabolism of cells in the desired direction. That is why we shift the glycolytic pathway of the cells in the wanted direction.

Without genetic interference

We shift protein galactosylation or mannosylation in the desired direction. We achieve this without genetic interference within the cells. There is no need to express exogenous glycosylation enzymes in the cells. Thus, without altering the master cell bank we can obtain the desired glycosylation profile.

First

in the world

Our specialised nutrient cocktails get formulated into novel cell culture media. We utilize these media to modify protein quality attributes.

These kinds of culture media are specifically designed to alter protein mannosylation or galacosylation.

NutriBalance


platform for media development

Quick, without compromises

Our modularly assembled platform enables us to be among the first to develop novel culture media. We utilize a toolbox taking into consideration the metabolism of the specified cell type, for which to develop our products. The resulting media can be produced in a record time while surpassing other alternatives on the market.

Balance, our core philosophy

Our in depth understanding of cellular metabolic pathways enable us to develop media recipes, that correspond to the metabolic needs of the particular cell type.

Our media recipes are not only optimised for cell growth but also optimised for an efficient metabolism.

In all of our media the cells generate more cellular energy and less metabolic waste products. Across all used cells the acidic waste is reduced enabling the pH in the bioreactor to remain constant. This benefit simplifies cell cultivation on a large scale.

Modular

quick and powerful.

All of our culture media are products of our NutriBalance platform.
NutriBalance is built modularly, thus media development is simplified. Most importantly media development for a novel cell line doesn´t take a lot of time for us anymore. We combine modules by taking the specific cell metabolism into account with an algorithm. This enables us to find the appropriate culture medium for the cell line in a record time.

Universal


more than animal cells

Our NutriBalance media platform is universally applicable to develop any novel culture medium. It is applicable for not only animal cells but also stem cells, bacteria as well as yeast.

We have also developed novel media for unusual cell lines like Vero suspension cells, MDCK suspensison cells and MRC-5 suspension cells.

The cell science company

What we do

We are a life science company with proprietary technology, know-how and experience in manufacturing therapeutic proteins. We accomplish this in the shortest time with the most economic measures.

We have developed platform technologies for vaccine and recombiant protein production. We provide our clients with production cells, culture media and our service to optimize protein glycosylation.

Who we are

Aziz Cayli, PhD, MBA
Founder and Chief scientific officer

Dr. Cayli started his venue into cell culture at GFB (Gesellschaft für biotechnologische Forschung) in Germany as a PhD student. His industry experience began at Roche Diagnostics in Penzberg, Germany where he transferred production processes from the US to Germany. Dr Cayli later worked at Boehringer Ingelheim in Biberach, Germany as head of the cell culture technology group. During this time he designed production processes to run on a 15.000 L scale. He later founded Cellca GmbH in Germany and developed one of the most powerful platform technologies in the world for cell line generation and media design.

Reinhard Vogt
Chief Business Officer

Mr. Vogt was Executive VP and Member of the Board of Sartorius Stedim Biotech S.A., Germany. Mr. Vogt brings a wealth of industry knowledge, technology deal-side expertise and numerous technology licenses, acquisitions and integrations derived from one of the industry’s largest players. He transformed the filtration business from $30 million in the 90s, to what is now today the Sartorius Bioprocess Business of $1.2 billion. He served as Executive VP and Member of the Board of Sartorius AG for over 10 years and has served as Director of 15 companies. Mr. Vogt also established operations in Australian, China, India, Korea and Turkey.

Cem Erdem
Founder and chief executive officer

Mr. Erdem is the former head of bioprocess division sales at Sartorius Turkey. He started his career as a management trainee at Sartorius Turkey. During his 16 year career at Sartorius Turkey Mr. Erdem worked as a project manager, sales manager as well as director of sales. Thanks to his vast experience in sales and marketing in the industry Mr. Erdem co-founded Florabio as well as Florabio Academy with Dr. Cayli and Dr. Walter.

Florabio AS
Gülbahce Mah. Gülbahce Cad. Teknopark Izmir No: 01/43/04 35430 Urla/Izmir-TURKEY

info@florabio.com.tr
Phone: +90 232 502 3321